Format

Send to

Choose Destination
Transfus Clin Biol. 2016 Feb;23(1):13-9. doi: 10.1016/j.tracli.2015.12.001. Epub 2016 Jan 5.

Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): Implications for blood transfusion safety.

Author information

1
Laboratory Medicine and Epidemiology/Biostatistics, University of California San Francisco and Senior investigator, Blood Systems Research Institute, San Francisco, USA. Electronic address: murphy@ucsf.edu.

Abstract

Many countries currently perform antibody screening for HTLV-1 infection in blood donors, and this intervention is likely cost-effective in preventing HTLV-1 related diseases in high prevalence countries. However, a number of high-income countries with low prevalence of HTLV-1 infection also perform universal HTLV-1 screening and debate has arisen regarding the cost-effectiveness of these strategies. Filter-based leukoreduction is likely to substantially reduce HTLV-1 transmission by removing infected lymphocytes, but actual laboratory data on its efficacy is currently lacking. Similarly, cost-effectiveness research on HTLV-1 prevention strategies is limited by poor data on prevalence, transmission efficacy and the cost of treating HTLV1 diseases.

KEYWORDS:

Blood transfusion; Dépistage immunologique; HTLV-1; Immunoassay; Prevention and control; Prévention et contrôle; Transfusion sanguine

PMID:
26778839
PMCID:
PMC5042452
DOI:
10.1016/j.tracli.2015.12.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center